Peeling paint, debris among problems found at U.S. plant making J&J COVID-19 vaccine -FDA

A plant making Johnson & Johnson's COVID-19 vaccine must fix a long list of problems including peeling paint, poor sanitation and brown and black substances on surfaces, the U.S. Food and Drug Administration said in a 12-page report on the facility, which has paused manufacturing.

Emergent Biosolutions, which owns the plant, has been seeking regulatory authorization to make the J&J vaccine there. It stopped production at the plant recently, saying the FDA had asked it to do so after an inspection. Johnson & Johnson reiterated on Wednesday it was working to establish a global supply chain in which 10 manufacturing sites would be involved in the production of its COVID-19 vaccine, in addition to its plant in Leiden, the Netherlands.